Skip to main content
Premium Trial:

Request an Annual Quote

Bruker BioSciences Revenues Climb 16 Percent, Earnings Rise in Q4 of 2004

NEW YORK, March 3 (GenomeWeb News) - Bruker BioSciences yesterday reported increased revenues and earnings for the fourth quarter of 2004.

 

Revenues for the quarter were $85.8 million, 16 percent up from $73.7 million during the same period in 2003. Of these, Bruker Daltonics contributed $44.8 million, a 7-percent increase year over year, and Bruker AXS contributed $41.8 million, a 32-percent increase over the previous year's quarter.

 

Research and development expenses climbed to $11.7 million, up from $9.9 million during the year-ago quarter.

 

Bruker's net income for the quarter was $800,000, or $.01 per diluted share, up from $300,000, or $0 per diluted share, in the fourth quarter of 2003.

 

As of Dec. 31, Bruker had $78.8 million in cash and short-term investments.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.